Cargando…

Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study

Pediatric developmental epileptic encephalopathies are often refractory to treatment despite stable antiseizure therapy. The safety profile of diazepam nasal spray (Valtoco) as rescue therapy for seizure clusters was described in a long-term safety study. This post hoc analysis assessed safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tarquinio, Daniel, Wheless, James W., Segal, Eric B., Misra, Sunita N., Rabinowicz, Adrian L., Carrazana, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466939/ https://www.ncbi.nlm.nih.gov/pubmed/37455404 http://dx.doi.org/10.1177/08830738231185424

Ejemplares similares

Pharmacokinetics and safety of VALTOCO (NRL‐1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri‐ictal) and nonseizure (interictal) conditions: A phase 1, open‐label study
por: Hogan, Robert Edward, et al.
Publicado: (2020)

Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
por: Wheless, James W., et al.
Publicado: (2021)

Consistent safety and tolerability of Valtoco(®) (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long‐term, open‐label, repeat‐dose safety study
por: Miller, Ian, et al.
Publicado: (2021)

Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long‐term, open‐label safety study
por: Segal, Eric B., et al.
Publicado: (2021)

Lack of clinically relevant differences in safety and pharmacokinetics after second‐dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis
por: Cascino, Gregory D., et al.
Publicado: (2022)

Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out‐of‐hospital seizure clusters: Results from a phase 3, open‐label, repeat‐dose safety study
por: Sperling, Michael R., et al.
Publicado: (2022)

Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters
por: Misra, Sunita N., et al.
Publicado: (2022)

Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters
por: Cloyd, James, et al.
Publicado: (2021)

Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers
por: Hogan, R. Edward, et al.
Publicado: (2020)

Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL‐1 to Healthy Volunteers
por: Tanimoto, Sarina, et al.
Publicado: (2020)

Inherited Developmental and Epileptic Encephalopathies
por: Bartolini, Emanuele
Publicado: (2021)

Diazepam induced sleep spindle increase correlates with cognitive recovery in a child with epileptic encephalopathy
por: Stoyell, S. M., et al.
Publicado: (2021)

Use of intranasal rescue therapy for seizure clusters in students with epilepsy: Nurses’ knowledge, perceptions, and practice
por: Santilli, Nancy, et al.
Publicado: (2023)

Tubulinopathy Presenting as Developmental and Epileptic Encephalopathy
por: Hung, Kun-Long, et al.
Publicado: (2022)

VALTOCO(®) (Diazepam Nasal Spray) for the Acute Treatment of Intermittent Stereotypic Episodes of Frequent Seizure Activity
por: Cornett, Elyse M., et al.
Publicado: (2021)

Treatment of Seizure Clusters in Epilepsy: A Narrative Review on Rescue Therapies
por: Becker, Danielle A., et al.
Publicado: (2023)

Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial
por: Scheffer, Ingrid E., et al.
Publicado: (2021)

Pediatric-Onset Epilepsy and Developmental Epileptic Encephalopathies Followed by Early-Onset Parkinsonism
por: Spagnoli, Carlotta, et al.
Publicado: (2023)

Importance of targeted next-generation sequencing in pediatric patients with developmental epileptic encephalopathy
por: Bariş, Savaş, et al.
Publicado: (2023)

Dravet Syndrome: A Developmental and Epileptic Encephalopathy
por: Lopez-Santiago, Luis, et al.
Publicado: (2019)

STXBP1-Related Developmental and Epileptic Encephalopathy
por: Wild, Brittani, et al.
Publicado: (2019)

KCNQ2‐DEE: developmental or epileptic encephalopathy?
por: Berg, Anne T., et al.
Publicado: (2021)

RARS1‐related developmental and epileptic encephalopathy
por: Wan, Lin, et al.
Publicado: (2023)

SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy
por: Vlaskamp, Danique R.M., et al.
Publicado: (2019)

Surgical Treatment of Pediatric Epileptic Encephalopathies
por: Fridley, J., et al.
Publicado: (2013)

Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012)

Epidemiology and etiology of infantile developmental and epileptic encephalopathies in Tasmania
por: Ware, Tyson L., et al.
Publicado: (2019)

Biallelic mutations in PIGP cause developmental and epileptic encephalopathy
por: Krenn, Martin, et al.
Publicado: (2019)

Investigating Developmental and Epileptic Encephalopathy Using Drosophila melanogaster
por: Takai, Akari, et al.
Publicado: (2020)

A 2020 View on the Genetics of Developmental and Epileptic Encephalopathies
por: Happ, Hannah C., et al.
Publicado: (2020)

Solute carrier transporter disease and developmental and epileptic encephalopathy
por: Gan, Yajing, et al.
Publicado: (2022)

Advances toward precision therapeutics for developmental and epileptic encephalopathies
por: Bertocchi, Ilaria, et al.
Publicado: (2023)

Future opportunities for research in rescue treatments
por: Wheless, James W., et al.
Publicado: (2022)

Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters—a randomized, double‐blind, placebo‐controlled trial
por: Detyniecki, Kamil, et al.
Publicado: (2019)

PURA-Related Developmental and Epileptic Encephalopathy: Phenotypic and Genotypic Spectrum
por: Johannesen, Katrine M., et al.
Publicado: (2021)

Improvement of Intranasal Drug Delivery with Intravail(®) Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System
por: Rabinowicz, Adrian L., et al.
Publicado: (2021)

Optimizing Absorption for Intranasal Delivery of Drugs Targeting the Central Nervous System Using Alkylsaccharide Permeation Enhancers
por: Madden, Stuart, et al.
Publicado: (2023)

PLPBP mutations cause variable phenotypes of developmental and epileptic encephalopathy
por: Shiraku, Hiroshi, et al.
Publicado: (2018)

Defining and expanding the phenotype of QARS-associated developmental epileptic encephalopathy
por: Johannesen, Katrine M., et al.
Publicado: (2019)

Overlaps, gaps, and complexities of mouse models of Developmental and Epileptic Encephalopathy
por: Wang, Wanqi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tpf0hs1d5484t6qfm9mmvnijvl